It is possible that multiple TCTP targeting agents may be combined to increase the effect: for example, preclinical studies have shown that the combination of artesunate, a specific inhibitor of TCTP (see above), and rapamycin was more effective in killing malignant peripheral nerve sheath tumors (MPNSTs) compared to the effect induced by exposure to a single drug[33] [Table 4]. Here, TPT1 is linked to malignant peripheral nerve sheath tumor.